Dynamic monitoring of PD‐L1 and Ki67 in circulating tumor cells of metastatic non‐small cell lung cancer patients treated with pembrolizumab

Programmed cell death protein ligand‐1 (PD‐L1) expression in non‐small cell lung cancer (NSCLC) tumors guides treatment selection. PD‐L1 expression in circulating tumor cells (CTCs) may provide further information. We have explored PD‐L1 and marker of proliferation Ki‐67 (Ki67; also known as MKI67)...

Descripción completa

Detalles Bibliográficos
Autores principales: Spiliotaki, Maria, Neophytou, Christiana Michael, Vogazianos, Paris, Stylianou, Ioannis, Gregoriou, Gregoria, Constantinou, Andreas Ioannou, Deltas, Constantinos, Charalambous, Haris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158784/
https://www.ncbi.nlm.nih.gov/pubmed/36177552
http://dx.doi.org/10.1002/1878-0261.13317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158784/
https://www.ncbi.nlm.nih.gov/pubmed/36177552
http://dx.doi.org/10.1002/1878-0261.13317

Ejemplares similares